Literature DB >> 7539119

Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.

R A Van Etten1, J Debnath, H Zhou, J M Casasnovas.   

Abstract

We have introduced two loss-of-function point mutations from highly conserved regions of the src homology 3 (SH3) domains of the Caenorhabditis elegans sem-5 gene into the SH3 domain of the murine type IV c-abl tyrosine kinase proto-oncogene. One of the mutations, P131L, activated abl to transform fibroblasts while the other, G128R, did not. When combined with independent activating mutations in the c-abl kinase domain or NH2-terminus, the G128R mutation blocked transformation by the double mutant, suggesting that the G128R mutant was unable to transform cells for trivial reasons. The c-Abl G128R mutant, like wild type c-Abl protein, was localized to the nucleus and actin cytoskeleton and had normal tyrosine kinase activity in vitro, while the transforming c-Abl P131L protein was localized exclusively to the cytoplasm and exhibited decreased in vitro kinase activity. By real-time biospecific interaction analysis, the wild type Abl SH3 domain bound to two proteins containing proline-rich motifs with dissociation constants of 0.2 and 17 microM; the G128R mutant bound with 50-fold lower affinity, and no binding was detected by the P131L mutant. Both mutations completely abolished binding of the Abl SH3 domain to proline-rich target proteins in a filter-binding assay. These results suggest that the transforming activity of Abl is regulated in vivo by an inhibitor protein which associates with the SH3 domain via a proline-rich sequence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539119

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.

Authors:  Y Nie; H H Li; C M Bula; X Liu
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 2.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

3.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl.

Authors:  P Dupraz; N Rebai; S J Klein; N Beaulieu; P Jolicoeur
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Abl kinases regulate actin comet tail elongation via an N-WASP-dependent pathway.

Authors:  Elizabeth A Burton; Timothy N Oliver; Ann Marie Pendergast
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway.

Authors:  Yingzhu Li; Nancy Clough; Xiaolin Sun; Weidong Yu; Brian L Abbott; Christopher J Hogan; Zonghan Dai
Journal:  J Cell Sci       Date:  2007-03-27       Impact factor: 5.285

7.  The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity.

Authors:  S T Wen; R A Van Etten
Journal:  Genes Dev       Date:  1997-10-01       Impact factor: 11.361

8.  c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein.

Authors:  J Zhu; S K Shore
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

9.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Authors:  Sergei Roumiantsev; Neil P Shah; Mercedes E Gorre; John Nicoll; Bradley B Brasher; Charles L Sawyers; Richard A Van Etten
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.